Anastrozole therapy and lipid profile: an update

Wojtacki, Janusz; Leśniewski-Kmak, Krzysztof; Pawlak, Wojciech; Nowicka, Elżbieta

doi:10.1016/s1359-6349(04)90900-7

Cited by 26 publications

(13 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Wojtacki et al [15] reported on the effects of adjuvant anastrozole on lipid profile in 51 postmenopausal patients pretreated with tamoxifen. Measurements were taken at baseline and 24, 60 and 130 weeks.…”

Section: Discussionmentioning

confidence: 99%

Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial

et al. 2005

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial

et al. 2005

View full text Add to dashboard Cite

“…23,24 In a low-grade hypercholesterolemia the same is not reported for exemestane or anastrozole. [13][14][15][16] However, recent evidences raise the possibility that the impact on lipid profile of aromatase inhibitors is due to the absence of tamoxifen protective effect rather than to a true aromatase inhibitor toxicity. 17 In our study population baseline cholesterol levels in patients treated with letrozole as last previous hormoe treatment, were similar to those of exemestane group.…”

Section: Fulvestrant and Lipid Profile In Advanced Breast Cancermentioning

confidence: 99%

Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone receptor-positive metastatic breast cancer patients

Camerini¹,

Rondini²,

Garrone³

et al. 2009

Cancer Biology & Therapy

View full text Add to dashboard Cite

show abstract

“…Like the cardiovascular effects of these drugs, the effects of AIs on lipids differ among agents, and vary among the individual studies. In the ATAC trial, anastrozole was associated with a greater incidence of hypercholesterolemia (9%) than with tamoxifen (3%; p Ͻ .0001), whereas other studies show no clear pattern of difference [58,69]. Letrozole has mixed effects on total cholesterol, with one study showing an elevation in total cholesterol, compared with tamoxifen, but no difference compared with placebo [59,60].…”

Section: Cardiovascular Effectsmentioning

confidence: 99%

Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer

Lenihan¹,

Esteva

2008

The Oncologist

View full text Add to dashboard Cite

Adjuvant systemic therapies for the treatment of earlystage breast cancer (EBC) effectively treat the tumor and significantly decrease the risk for recurrence. However, some of these treatments are associated with an increased risk of cardiovascular adverse events. Cardiovascular complications related to cancer therapy may be a prominent concern in postmenopausal women with existing cardiovascular disease or in those who are at high risk for developing cardiovascular disease. The increased risk for cardiac toxicity in women receiving radiation, anthracyclines, and/or trastuzumab for the adjuvant treatment of EBC is well established. The risk of thromboembolic disease is higher in patients with estrogen receptor-positive EBC receiving tamoxifen in the adjuvant setting, whether it is given before or instead of an aromatase inhibitor. In addition, while available data suggest no substantial differences in the risk for ischemic cardiovascular events between aromatase inhibitors and tamoxifen, investigation is still ongoing. Based on this information, it is important for health care providers to understand the cardiovascular risks of treatment and how to monitor at-risk patients, particularly when multiple agents are used in combination or in succession. Improving cardiovascular outcomes in patients with EBC requires cardiovascular risk assessment, management, and long-term follow-up care. Because of the multimodal treatment of EBC patients, their care requires a multidisciplinary approach to reduce not only the risk for breast cancer recurrence but also the risk for treatment-related cardiac toxicities.

show abstract

Anastrozole therapy and lipid profile: an update

Cited by 26 publications

References 0 publications

Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial

Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial

Fulvestrant treatment is associated with cholesterol plasma level reduction in hormone receptor-positive metastatic breast cancer patients

Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer

Contact Info

Product

Resources

About